Cholesterol Ester Transfer Proteins
"Cholesterol Ester Transfer Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins that bind to and transfer CHOLESTEROL ESTERS between LIPOPROTEINS such as LOW-DENSITY LIPOPROTEINS and HIGH-DENSITY LIPOPROTEINS.
| Descriptor ID |
D053480
|
| MeSH Number(s) |
D09.400.430.750 D12.776.124.197 D12.776.157.165 D12.776.395.199
|
| Concept/Terms |
Cholesterol Ester Transfer Proteins- Cholesterol Ester Transfer Proteins
- Cholesteryl Ester Exchange Protein
- Cholesteryl Ester Transfer Protein
- Cholesterol Ester Transport Protein, CETP
|
Below are MeSH descriptors whose meaning is more general than "Cholesterol Ester Transfer Proteins".
Below are MeSH descriptors whose meaning is more specific than "Cholesterol Ester Transfer Proteins".
This graph shows the total number of publications written about "Cholesterol Ester Transfer Proteins" by people in this website by year, and whether "Cholesterol Ester Transfer Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 1 | 0 | 1 |
| 2011 | 3 | 1 | 4 |
| 2012 | 1 | 1 | 2 |
| 2013 | 2 | 1 | 3 |
| 2016 | 1 | 2 | 3 |
| 2017 | 1 | 1 | 2 |
| 2018 | 0 | 1 | 1 |
| 2023 | 1 | 0 | 1 |
| 2024 | 0 | 2 | 2 |
| 2025 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cholesterol Ester Transfer Proteins" by people in Profiles.
-
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol. 2025 Oct 07; 86(14):1046-1056.
-
Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics. Am Heart J. 2025 Dec; 290:325-338.
-
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. N Engl J Med. 2025 Jul 03; 393(1):51-61.
-
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024 08; 274:32-45.
-
HDL Therapeutics - Time for a Curtain Call or Time to Reconceptualize? N Engl J Med. 2024 05 02; 390(17):1622-1623.
-
Serum amyloid A augments the atherogenic effects of cholesteryl ester transfer protein. J Lipid Res. 2023 05; 64(5):100365.
-
Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial. BMJ Open Diabetes Res Care. 2020 03; 8(1).
-
Serum Amyloid A Is an Exchangeable Apolipoprotein. Arterioscler Thromb Vasc Biol. 2018 08; 38(8):1890-1900.
-
Sex Differences in Blood HDL-c, the Total Cholesterol/HDL-c Ratio, and Palmitoleic Acid are Not Associated with Variants in Common Candidate Genes. Lipids. 2017 Dec; 52(12):969-980.
-
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med. 2017 05 18; 376(20):1933-1942.